

**Day One  
Tuesday December 5<sup>th</sup> 2017**

**08.00 Breakfast & Registration**

**09.00 Chair's Opening Remarks**  
Frank Tufaro, CEO, DNatrix

**09.30 IMLYGIC, from Bench to Bedside: Cancer Treatment Goes Viral**  
Jennifer Gansert, Executive Director, Global Lead, Amgen

**Combination Therapies: Checkpoint Modulation & Beyond**

**10.00 Pexa-Vec: A Multi-Mechanistic Immunotherapeutic Modulator of the Tumor Microenvironment**  
Naomi De Silva, Associate Director, Sillajen

**10.30 Morning Refreshments & Speed Networking**

**11.30 New Hope from Innovative Virotherapy and Immunotherapy for Glioblastoma**  
Benjamin Gesundheit, COO, Rapo Yerapeh , Go Viral Ltd

**12.00 VSV-GP: A Game Changer for Immuno Oncology**  
Philipp Mueller, Principal Scientist, R&D, Boehringer Ingelheim

**12.30 Lunch & Networking**

**OVs and the Tumor Microenvironment**

**13.30 An Oncolytic Virus Expressing a FAP-Specific T-Cell Engager to Target Stroma-Rich Tumors**  
Charles Morris, CDO, PsiOxus Therapeutics

**14.00 PeptiCRAd™: An Innovative Oncolytic Vaccine Platform to Refocus the Immune Response from Virus to Tumor**  
Sari Pesonen, VP, Scientific & Clinical Development , Valo Therapeutics

**14.30 T-Stealth™ Technology Promotes Synergy Between Oncolytic Viruses and Immuno-Stimulatory Agents**  
Matt Mulvey, CEO, Benevir Biopharm

**15.00 Afternoon Refreshments & Networking**

**15.30 Targeted Oncolytic Viro -Immunotherapy for the Treatment of Brain Tumors**  
Paola Grandi, Senior Director, Immunology/Virology, Oncorus

**OVs to Elicit True Immune Responses**

**16.00 Introducing Replimune's Next Generation "Immulytic™" Oncolytic Immunotherapy Platform**  
Rob Coffin, CEO, Replimune

- 16.30 Development Strategy of HF10, a Spontaneous Mutant Herpes Simplex Virus**  
Robert Andtbacka, Co-Director Melanoma Program & Melanoma Clinical Research Program,  
Huntsman Cancer Institute
- 17.00 Chair's Closing Remarks**  
Frank Tufaro, CEO, DNATRIX
- 17.15 End of Day 1**

**Day Two**  
**Wednesday December 6<sup>th</sup> 2017**

**08.00 Registration & Coffee**

**09.00 Chair's Opening Remarks**  
Frank Tufaro, CEO, DNATRIX

**Improving Delivery of OV's Intravenous vs. Intratumoral**

**09.30 Local LOAd703 Virus Administration Results in Enhanced Efficacy Compared to Systemic Treatment.**  
Angelica Loskog, CEO, Lokon Pharma

**10.00 Achieving the Right Viral Volumes and Dosages Effectively**  
Stephen Thorne, CEO, Western Oncolytics

**10.30 Morning Refreshments & Networking**

**11.00 PANEL: How Can We Improve The Efficacy of Oncolytic Virotherapies?**  
Moderator: Frank Tufaro, CEO, DNATRIX  
Rob Coffin, CEO, Replimune  
Charles Morris, CDO, PsiOxus Therapeutics  
Stephen Russell, CEO, Vyriad  
Matt Coffey, CEO, Oncolytics Biotech

**Clinical Trial Case Studies**

**12.00 Vaccinia Virus-based Oncolytic Immunotherapy: Ongoing Early and Late Stage Clinical Development**  
Monika Lusky, Director, Transgene

**12.30 Oncolytic Herpes Virus Therapy for Mesothelioma: A Phase 1/2a Trial of Intrapleural Administration of Seprehvir**  
Joe Conner, VP, Oncolytic Immunotherapy, Virttu Biologics, A Sorrento Company

**13.00 Lunch & Networking**

**14.00 VSV-IFN $\beta$ -NIS and MV-NIS: A Tale of Two Paradigms**  
Stephen Russell, CEO, Vyriad

**14.30 Immune and Genetic Markers in Randomized Clinical Studies using REOLYSIN<sup>®</sup>**  
Matt Coffey, CEO, Oncolytics Biotech

**Toca-511: A Translational Case Study from Bench to Bedside**

**15.00 Retroviral Replicating Vectors: A Versatile Platform Technology for Immuno-Gene-Virotherapy**  
Noriyuki Kasahara, Professor, Departments of Cell Biology and Pathology, University of Miami

- 15.30 Ensuring Long Term Durable Responses and Corresponding Survival**  
Douglas Jolly, EVP, Research & Pharmaceutical Development, Tocagen
- 16.00 Chair's Closing Remarks: The Future of Oncolytic Virotherapies**  
Frank Tufaro, CEO, DNAtrix
- 16.15 Close of Summit**